A Research Study to Evaluate the Safety and Effectiveness of MK0217 to Prevent and Treat Bone Loss (0217-193)(COMPLETED)

Status:
Completed

Trial end date:
2003-08-01

Target enrollment:

Participant gender:

A research study to see how safe and effective MK0217 is when taken weekly for the prevention and treatment of steroid induced bone loss.

Phase 3

Merck Sharp & Dohme Corp.

Glucocorticoids